A5024283333- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- MRI in cancer diagnosis
- Genetic factors in colorectal cancer
- Colorectal Cancer Surgical Treatments
- Renal and related cancers
- Health Systems, Economic Evaluations, Quality of Life
- Urologic and reproductive health conditions
- Radiomics and Machine Learning in Medical Imaging
- Epigenetics and DNA Methylation
- Renal and Vascular Pathologies
- Multiple and Secondary Primary Cancers
- Radiation Dose and Imaging
- Colorectal Cancer Screening and Detection
- Cancer Genomics and Diagnostics
- Chronic Kidney Disease and Diabetes
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Radiation Therapy and Dosimetry
- Cerebral Venous Sinus Thrombosis
- Metastasis and carcinoma case studies
IRCCS Ospedale San Raffaele
2024-2025
Vita-Salute San Raffaele University
2024-2025
Uppsala University
2024-2025
Uppsala University Hospital
2025
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2025
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2024-2025
Surgical Science (Sweden)
2025
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2022
Objective To assess the diagnostic performance of 18F‐fluoro‐2‐deoxy‐ d ‐glucose (18F‐FDG) positron emission tomograpy (PET)/computed tomography (CT) in nodal staging before radical cystectomy (RC) and pelvic lymph node dissection (PLND) for bladder cancer (BCa). Materials Methods This analysis was based on a cohort 199 BCa patients undergoing RC bilateral PLND between 2015 2022. Neoadjuvant chemotherapy (NAC) or immunotherapy (NAI) administered after oncological evaluation. All received...
Objective To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort patients with high‐risk very‐high‐risk non‐muscle‐invasive bladder cancer (NMIBC) after previous Bacillus Calmette–Guérin (BCG) treatment. Materials Methods Data were retrospectively collected from 95 NMIBC, treated Gem/Doce at 12 centres between 2021 2024. Patients previously BCG who had completed full induction course received least one...
Abstract Background There has been a wide range in incidence of prostate-specific antigen (PSA) persistence and relapse after radical prostatectomy (RP) for prostate cancer (PCa). We aimed to describe prognostic implications PSA relapse. Methods Register-based cohort study Sweden men diagnosed with PCa between 2007 2020 who underwent RP. Risks were estimated using competing risk cumulative curves. Treatment or death other causes stratified according persistence, European Association Urology...
It is unknown if a period of active surveillance before prostatectomy for prostate cancer (PCa) worsens functional outcomes. The aim this study was to compare outcomes after primary vs delayed robot-assisted radical prostatectomy. We included men registered in the National Prostate Cancer Register Sweden with low and favorable intermediate-risk PCa who underwent 2018-2020 had filled questionnaire on patient-reported outcome measures. Multivariable logistic regression analysis used 2571...
To assess the oncological outcomes of patients with high-risk (HR) and very (VHR) non-muscle-invasive bladder cancer (NMIBC) treated upfront radical cystectomy (RC) vs Bacillus Calmette-Guérin (BCG) instillations from a contemporary European multicentre cohort. We conducted retrospective analysis 1491 diagnosed HR- or VHR-NMIBC database between 2015 2024. Patients were included if they received either RC at least five doses BCG. A 1:1 propensity score matching (PSM) according to clinically...
Swedish national guidelines provide evidence-based recommendations for standard of care; however, little is known about adherence to them. The aim this study was assess management prostate cancer (PCa). Data in the National Prostate Cancer Register (NPCR), that includes 98% all incident PCa cases Sweden, were used analyse men diagnosed between 2010 and 2023. A selection quality indicators displayed on public web page NPCR assessed. Active surveillance with low-risk an estimated life...
Objective To assess the incidence of acute kidney injury (AKI) and disease (AKD) following radical cystectomy (RC) in patients with muscle‐invasive bladder cancer (BCa). Materials Methods A consecutive cohort 840 undergoing RC for BCa at a tertiary institution (2010–2022) was analysed. Clinical variables, comorbidities, surgical techniques oncological regimens were recorded pre‐ post‐surgery. Serum creatinine estimated glomerular filtration rate (eGFR) assessed baseline, 24, 48 72 h, 6 days...
To evaluate the impact of discordant histological diagnoses between transurethral resection bladder tumour (TURBT) and radical cystectomy (RC) on cancer-specific mortality (CSM) in patients with cancer (BCa). We relied a multi-institutional database collecting data BCa who underwent TURBT subsequent RC from nine centres 2000 2023. tested concordance rates detecting urothelial carcinoma urinary (UCUB) as well non-UCUB hystological subtypes, using reference standard. Concordance was defined...
Background/Objectives: An 80-year-old man was admitted to our department after a salvage radical cystectomy for actinic cystitis due radiotherapy prostate cancer. He presented with two-month history of feculent debris in the right stoma and deteriorated general conditions, long past medical recurrent complicated urinary infections. Methods: Computer tomography (CT) abdomen revealed ureterocolic fistula along ureteral pelvic tract. A percutaneous nephrostomy tube placed. Due multiple previous...